Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (195) Arrow Down
Filter Results: (195) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (195)
    • News  (22)
    • Research  (151)
    • Events  (2)
  • Faculty Publications  (74)

Show Results For

  • All HBS Web  (195)
    • News  (22)
    • Research  (151)
    • Events  (2)
  • Faculty Publications  (74)
← Page 4 of 195 Results →
  • Research Summary

Regulatory negotiations and risk communication

In the pharmaceutical industry a drugs benefits and risks are constantly being weighed by companies, regulators, physicians and drug consumers. While companies and regulators must make decisions based on population statistics about drug outcomes, physicians and drug... View Details
  • September 1993
  • Supplement

Manufacturing at ALZA: The Right Prescription? (C)

By: Dorothy A. Leonard
ALZA, a drug delivery company, considers marketing its own and other companies' products. The primary issue is whether to build an internal sales force focused on a few niche markets, to finance a sales force through alliances, or to acquire a marketing company. View Details
Keywords: Mergers and Acquisitions; Product Marketing; Alliances; Research and Development; Salesforce Management; Business Strategy; Pharmaceutical Industry
Citation
Find at Harvard
Related
Leonard, Dorothy A. "Manufacturing at ALZA: The Right Prescription? (C)." Harvard Business School Supplement 694-021, September 1993.
  • January 2018 (Revised January 2019)
  • Case

ZappRx

By: Jeffrey J. Bussgang and Olivia Hull
In October 2015, ZappRx founder Zoe Barry is deciding between two business models for her health technology start-up. Her product, a software application that aims to expedite the prescription fulfillment process for patients with rare diseases, has attracted interest... View Details
Keywords: Speciality Drugs; Hub Services; Pivot; Speciality Prescriptions; Health Care and Treatment; Customization and Personalization; Internet and the Web; Business Model; Decision Choices and Conditions; Pharmaceutical Industry; Massachusetts
Citation
Educators
Purchase
Related
Bussgang, Jeffrey J., and Olivia Hull. "ZappRx." Harvard Business School Case 818-001, January 2018. (Revised January 2019.)
  • Research Summary

Current Research

Ian studies extrinsic rewards -- monetary incentives from formal compensation systems, as well as other formal and informal external rewards-- in order to help businesses understand the tensions and tradeoffs inherent in motivating employees. His research takes a... View Details

  • September 2005 (Revised June 2006)
  • Case

WuXi PharmaTech

By: Richard G. Hamermesh and Simin Zhou
WuXi Pharmatech has gone from zero to $21 million in sales in three years. The company must decide its growth strategy and how best to finance and organize for rapid growth. View Details
Keywords: Growth Management; Capital Markets; Problems and Challenges; Pharmaceutical Industry; China
Citation
Educators
Purchase
Related
Hamermesh, Richard G., and Simin Zhou. "WuXi PharmaTech." Harvard Business School Case 806-003, September 2005. (Revised June 2006.)
  • 19 Sep 2017
  • First Look

First Look at New Research and Ideas, September 19

in the pharmaceutical industry and lessen the strain both on patients and the healthcare system as a whole. However, doing so would require the company to raise capital, strengthen its sales force, and... View Details
Keywords: Sean Silverthorne
  • October 2009 (Revised July 2013)
  • Case

Gilead Sciences, Inc.: Access Program

By: V. Kasturi Rangan and Katharine Lee
Gilead Sciences, the U.S. leader in HIV/AIDS medicines, with global sales of $5.4 billion in 2009, had undertaken several innovative actions to make its anti-viral products available to over 100 low- and middle-income countries. Having reached nearly 680,000 patients... View Details
Keywords: Health Care and Treatment; Emerging Markets; Product; Sales; Competitive Strategy; Pharmaceutical Industry; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Rangan, V. Kasturi, and Katharine Lee. "Gilead Sciences, Inc.: Access Program." Harvard Business School Case 510-029, October 2009. (Revised July 2013.)
  • January 2009
  • Case

When Supply is of Public Interest: Roche & Tamiflu

The case focuses on the challenges of Roche maintaining a supply network for a global influenza pandemic response initiative based on its antiviral drug Tamiflu. The Roche group is a 40 billion CHF company consisting of a pharmaceutical division and a diagnostic... View Details
Keywords: Global Strategy; Health Pandemics; Distribution; Logistics; Production; Supply Chain Management; Performance Capacity; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Watson, Noel H., Laura Rock Kopczak, and Prashant Yadav. "When Supply is of Public Interest: Roche & Tamiflu." Harvard Business School Case 609-061, January 2009.
  • 28 Jul 2008
  • Research & Ideas

Making the Decision to Franchise (or not)

appears to be true when you get a new type of consumer for the same product." In the pharmaceutical industry, for example, selling medicine to both an independent general practitioner and a hospital will require a different organizational... View Details
Keywords: by Julia Hanna; Retail
  • May 1998 (Revised May 1999)
  • Case

Biopure Corp.

By: John T. Gourville
It is early 1998 and Biopure Corp., a small biopharmaceutical firm with no sales revenues in its ten-year history, has just received government approval to release Oxyglobin, a revolutionary new "blood substitute" designed to replace the need for donated animal blood... View Details
Keywords: Segmentation; Marketing Strategy; Engineering; Budgets and Budgeting; Sales; Transformation; Markets; Debates; Product Launch; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Gourville, John T. "Biopure Corp." Harvard Business School Case 598-150, May 1998. (Revised May 1999.)
  • 03 Apr 2007
  • First Look

First Look: April 3, 2007

Middle East: Measuring Sales Force Effectiveness Harvard Business School Case 106-063 Nutricia's Middle East and African region is transitioning from a trading to a customer focus. CEO Ernest Vandenbussche must decide how to market infant... View Details
Keywords: Martha Lagace
  • 12 Feb 2008
  • First Look

First Look: February 12, 2007

how personal taxes affect CEOs' decision to sell their vested equity and compare it against diversification, managerial overconfidence and other determinants of CEOs' sale of equity. While CEOs frequently sell large amounts of their... View Details
Keywords: Martha Lagace
  • 04 Jun 2013
  • Working Paper Summaries

Prosocial Bonuses Increase Employee Satisfaction and Team Performance

Keywords: by Lalin Anik, Lara B. Aknin, Michael I. Norton, Elizabeth W. Dunn & Jordi Quoidbach
  • January 2017
  • Supplement

Medtronic: Making the Big Leap Forward (B)

By: William W. George and Monica Baraldi
On December 1, 2014, Medtronic announced that it had completed a $17 billion bond sale to finance the Covidien acquisition, officially completed on January 26, 2015. Medtronic’s legal headquarters moved to Ireland, while its operational headquarters remained in... View Details
Keywords: Acquisition; Medtronic; Covidien; Mission; Tax Inversion; Business Strategy; Leadership; Mergers and Acquisitions; Integration; Pharmaceutical Industry; Republic of Ireland; Europe; Minnesota; United States
Citation
Purchase
Related
George, William W., and Monica Baraldi. "Medtronic: Making the Big Leap Forward (B)." Harvard Business School Supplement 317-074, January 2017.
  • Web

Faculty & Advisors | MBA

Crinetics Pharmaceuticals (NASDAQ: CRNX), among others. Earlier in her career Dr. Chang was a Project Leader at The Boston Consulting and a member of the Healthcare Practice. Dr. Chang trained clinically in internal medicine and... View Details
  • 16 Jan 2018
  • First Look

First Look at New Research and Ideas, January 16, 2018

companies offer a direct stake in the company's performance through stock, a share in profits, or both. Companies with employee stock ownership plans report significantly higher sales growth and higher revenue per employee than do... View Details
Keywords: Sean Silverthorne
  • December 2017 (Revised January 2018)
  • Case

Alltech

By: David E. Bell and Natalie Kindred
Alltech was a Lexington, Kentucky–based producer of supplements for animal feed, with revenues of over $2 billion (projected to reach $3 billion in 2018), sales in 120 countries, 5,000 employees, and 100 manufacturing plants worldwide. For nearly four decades, Alltech... View Details
Keywords: Alltech; United States; Agribusiness; Agriculture; Animal; Animal Agriculture; Animal Feed; Livestock; Family Business; Vertical Integration; Strategy; Growth; Feed Additives; Feed Supplements; Kentucky; Growth Strategy; Family Businesses; Animal-Based Agribusiness; Acquisition; Business Growth and Maturation; Business Model; Change Management; Trends; Governance; Entrepreneurship; Growth and Development; Intellectual Property; Leadership; Management; Markets; Organizational Culture; Private Ownership; Science; Quality; Risk and Uncertainty; Research; Sales; Pharmaceutical Industry; Pharmaceutical Industry; United States; Kentucky; Brazil; China
Citation
Educators
Purchase
Related
Bell, David E., and Natalie Kindred. "Alltech." Harvard Business School Case 518-001, December 2017. (Revised January 2018.)

    V. Kasturi Rangan

    Kash Rangan is the Malcolm P. McNair Professor of Marketing at the Harvard Business School. Formerly the chairman of the Marketing Department (1998-2002), he is now the co-chairman of the school's Social Enterprise Initiative. He has taught in a wide variety of MBA... View Details

    Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals

      John T. Gourville

      John Gourville is the Albert J. Weatherhead, Jr. Professor of Business Administration at the Harvard Business School.  He joined the HBS Marketing Unit in 1995 after receiving his Ph.D. at the University of Chicago in marketing and behavioral research.  His most... View Details

      Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
      • 14 Aug 2007
      • First Look

      First Look: August 14, 2007

      shareholders? In the Johns Manville bankruptcy, shareholder equity was wiped out entirely. Purchase this case: http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=807090 WuXi PharmaTech Harvard Business School Case 806-003 WuXi Pharmatech has gone from zero... View Details
      Keywords: Martha Lagace
      • ←
      • 4
      • 5
      • …
      • 9
      • 10
      • →
      ǁ
      Campus Map
      Harvard Business School
      Soldiers Field
      Boston, MA 02163
      →Map & Directions
      →More Contact Information
      • Make a Gift
      • Site Map
      • Jobs
      • Harvard University
      • Trademarks
      • Policies
      • Accessibility
      • Digital Accessibility
      Copyright © President & Fellows of Harvard College.